U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
The FDA approved AbbVie's JUVMO (tavapadon), the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease. Approval rests on the Phase 3 TEMPO program: JUVMO significantly improved daily functioning scores versus placebo and increased 'on' time without troublesome dyskinesia by 1.7 hours versus 0.6 hours in TEMPO-3. At 85 weeks, 93% of patients on JUVMO plus levodopa had not increased their levodopa dose, supporting a differentiated, levodopa-sparing profile. AbbVie expects a U.S.
Key figures
- Drug Name
- JUVMO (tavapadon)
- Phase Of Trial
- Phase 3
- Us launch timing
- October 2026
- On time gain tem3
- 1.7 hours vs 0.6 hours placebo
- Levodopa non escalation 85wk
- 93%
- Worldwide parkinsons patients
- more than 11 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.